Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs

Nutrition and Cancer

Volumn 62, Issue 7, 2010, Pages 919-930

  Goel, Ajay ^a   Aggarwal, Bharat B ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BUTYRIC ACID; CAMPTOTHECIN; CELECOXIB; CHLORMETHINE; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MELPHALAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SULFINOSINE; THALIDOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIZATION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DOWN REGULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; GAMMA RADIATION; GLIOMA; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG CANCER; LYMPHOMA; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION PROTECTION; RADIOSENSITIZATION; RENAL PROTECTION; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; CURCUMIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS;

CURCUMA LONGA; RODENTIA;

EID: 77958011209     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.509835     Document Type: Review

References (84)

1. Rahman I, Biswas SK, and Kirkham PA: Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 72, 1439-1452, 2006. (Pubitemid 44666744)
2. Tirkey N, Kaur G, Vij G, and Chopra K: Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol 5, 15, 2005.
3. Brouet I and Ohshima H: Curcumin, an anti-tumour promoter and antiinflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206, 533-540, 1995.
4. Dikshit M, Rastogi L, Shukla R, and Srimal RC: Prevention of ischaemiainduced biochemical changes by curcumin and quinidine in the cat heart. Indian J Med Res 101, 31-35, 1995.
5. Sreejayan xx and Rao MN: Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 49, 105-107, 1997.
6. Chen J, Bai H, Wang C, and Kang J: Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 61, 710-716, 2006.
7. Chen J, Tang XQ, Zhi JL, Cui Y, Yu HM, et al.: Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 11, 943-953, 2006.
8. Divya CS and Pillai MR: Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog 45, 320-332, 2006.
9. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, and Hikino H: Antihepatotoxic principles of Curcuma longa rhizomes. Planta Med 49, 185-187, 1983. (Pubitemid 14220766)
10. Srivastava R, Dikshit M, Srimal RC, and Dhawan BN: Anti-thrombotic effect of curcumin. Thromb Res 40, 413-417, 1985.
11. Venkatesan N: Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124, 425-427, 1998.
12. Deodhar SD, Sethi R, and Srimal RC: Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71, 632-634, 1980.
13. Chan MM, Adapala NS, and Fong D: Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania. Parasitol Res 96, 49-56, 2005.
14. Singh S and Khar A: Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 6, 259-270, 2006.
15. Goel A, Kunnumakkara AB, and Aggarwal BB: Curcumin as "curecumin": from kitchen to clinic. Biochem Pharmacol 75, 787-809.
16. Gottesman MM, Ludwig J, Xia D, and Szakacs G: Defeating drug resistance in cancer. Discov Med 6, 18-23, 2006.
17. Theodoulou M, Batist G, Campos S, Winer E, Welles L, et al.: Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer 9, 101-107, 2009.
18. Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2, 101-112, 2002.
19. Davies A, Cifaldi MA, Segurado OG, and Weisman MH: Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 36, 16-26, 2009.
20. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, et al.: Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 6, 1378-1384, 2008.
21. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, and Griffin JD: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7, 345-356, 2007.
22. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043, 2007.
23. Gottesman MM, Fojo T, and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48-58, 2002.
24. Raguz S and Yague E: Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99, 387-391, 2008.
25. Al-Hajj M and Clarke MF: Self-renewal and solid tumor stem cells. Oncogene 23, 7274-7282, 2004.
26. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al.: Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821-5828, 2003.
27. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, et al.: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21, 926-935, 2007.
28. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009.
29. Howells LM, Mitra A, and Manson MM: Comparison of oxaliplatin-and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Cancer 2007.
30. Li L, Ahmed B, Mehta K, and Kurzrock R: Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6, 1276-1282, 2007.
31. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, et al.: Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122, 267-273, 2008.
32. Du B, Jiang L, Xia Q, and Zhong L: Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 52, 23-28, 2006.
33. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, et al.: Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 11, 6738-6744, 2005.
34. Shpitz B, Giladi N, Sagiv E, Lev-Ari S, Liberman E, et al.: Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 74, 140-144, 2006.
35. Koo JY, Kim HJ, Jung KO, and Park KY: Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food 7, 117-121, 2004.
36. Lev-Ari S, Zinger H, Kazanov D, Yona D, Ben-Yosef R, et al.: Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 59 (2 Suppl), S276-S280, 2005.
37. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, et al.: Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 25, 411-418, 2007.
38. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, et al.: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67, 3853-3861, 2007.
39. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, et al.: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells: analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 224, 53-65, 2005.
40. Holcomb B, Yip-Schneider MT, Matos JM, Dixon J, Kennard J, et al.: Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J Gastrointest Surg 12, 288-296, 2008.
41. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, et al.: Curcumin enhances cytotoxicity of chemotherapeutic agentsin prostate cancer cells by inducing p21 (WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate 51, 211-218, 2002.
42. Li M, Zhang Z, Hill DL, Wang H, and Zhang R: Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67, 1988-1996, 2007.
43. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al.: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490-7498, 2005.
44. Chirnomas D, Taniguchi T, del, V, Vaidya AP, Vasserman M, et al.: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5, 952-961, 2006.
45. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, et al.: Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62, 3868-3875, 2002.
46. Chan MM, Fong D, Soprano KJ, Holmes WF, and Heverling H: Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194, 63-70, 2003.
47. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, et al.: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13, 3423-3430, 2007.
48. Venkatraman M, Anto RJ, Nair A, Varghese M, and Karunagaran D: Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatininduced apoptosis. Mol Carcinog 44, 51-59, 2005.
49. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, et al.: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280, 6301-6308, 2005.
50. Sen S, Sharma H, and Singh N: Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 331, 1245-1252, 2005.
51. Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, et al.: Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 7, 1024-1032, 2008.
52. Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y, et al.: Curcumin sensitizes lung cancer cells to cisplatininduced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest 27, 624-635, 2009.
53. Kamat AM, Sethi G, and Aggarwal BB: Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6, 1022-1030, 2007.
54. Dhandapani KM, Mahesh VB, and Brann DW: Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102, 522-538, 2007.
55. Bharti AC, Donato N, Singh S, and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101, 1053-1062, 2003.
56. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, et al.: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8, 959-970, 2009.
57. Indap MA and Barkume MS: Efficacies of plant phenolic compounds on sodium butyrate induced anti-tumour activity. Indian J Exp Biol 41, 861-864, 2003.
58. Everett PC, Meyers JA, Makkinje A, Rabbi M, and Lerner A: Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol 82, 23-30, 2007.
59. Kuhad A, Pilkhwal S, Sharma S, Tirkey N, and Chopra K: Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 55, 10150-10155, 2007.
60. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, et al.: Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 14, 2128-2136, 2008.
61. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, and Ahmed MM: Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23, 1599-1607, 2004.
62. Javvadi P, Segan AT, Tuttle SW, and Koumenis C: The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 73, 1491-1501, 2008.
63. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, and Herman TS: Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther 7, 569-576, 2008.
64. Chan WH, Wu CC, and Yu JS: Curcumin inhibits UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermoid carcinoma A431 cells. J Cell Biochem 90, 327-338, 2003.
65. Chan WH and Wu HJ: Anti-apoptotic effects of curcumin on photosensitized human epidermal carcinoma A431 cells. J Cell Biochem 92, 200-212, 2004.
66. Dujic J, Kippenberger S, Hoffmann S, Ramirez-Bosca A, Miquel J, et al.: Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light. J Invest Dermatol 2007.
67. Dujic J, Kippenberger S, Ramirez-Bosca A, Diaz-Alperi J, Bereiter-Hahn J, et al.: Curcumin in combination with visible light inhibits tumor growth in a xenograft tumor model. Int J Cancer 124, 1422-1428, 2009.
68. Park K and Lee JH: Photosensitizer effect of curcumin on UVB-irradiated HaCaT cells through activation of caspase pathways. Oncol Rep 17, 537-540, 2007.
69. Khafif A, Hurst R, Kyker K, Fliss DM, Gil Z, et al.: Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg 132, 317-321, 2005.
70. van't LB, Blijlevens NM, Marteijn J, Timal S, Donnelly JP, et al.: Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia 18, 276-284, 2004.
71. Venkatesan N, Punithavathi D, and Arumugam V: Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 129, 231-234, 2000.
72. Punithavathi D, Venkatesan N, and Babu M: Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 131, 169-172, 2000.
73. Parshad R, Sanford KK, Price FM, Steele VE, Tarone RE, et al.: Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells. Anticancer Res 18, 3263-3266, 1998.
74. Srinivasan M, Rajendra PN, and Menon VP: Protective effect of curcumin on gamma-radiation induced DNA damage and lipid peroxidation in cultured human lymphocytes. Mutat Res 611, 96-103, 2006.
75. Kunwar A, Narang H, Priyadarsini KI, Krishna M, Pandey R, et al.: Delayed activation of PKCdelta and NFkappaB and higher radioprotection in splenic lymphocytes by copper (II)-Curcumin (1:1) complex as compared to curcumin. J Cell Biochem 2007.
76. Abraham SK, Sarma L, and Kesavan PC: Protective effects of chlorogenic acid, curcumin and beta-carotene against gamma-radiation-induced in vivo chromosomal damage. Mutat Res 303, 109-112, 1993.
77. Thresiamma KC, George J, and Kuttan R: Protective effect of curcumin, ellagic acid and bixin on radiation induced genotoxicity. J Exp Clin Cancer Res 17, 431-434, 1998.
78. Thresiamma KC, George J, and Kuttan R: Protective effect of curcumin, ellagic acid and bixin on radiation induced toxicity. Indian J Exp Biol 34, 845-847, 1996.
79. Inano H and Onoda M: Radioprotective action of curcumin extracted from Curcuma longa LINN: inhibitory effect on formation of urinary 8-hydroxy-2-deoxyguanosine, tumorigenesis, but not mortality, induced by gamma-ray irradiation. Int J Radiat Oncol Biol Phys 53, 735-743, 2002.
80. Rezvani M and Ross GA: Modification of radiation-induced acute oral mucositis in the rat. Int J Radiat Biol 80, 177-182, 2004.
81. Jagetia GC and Rajanikant GK: Role of curcumin, a naturally occurring phenolic compound of turmeric in accelerating the repair of excision wound, in mice whole-body exposed to various doses of gamma-radiation. J Surg Res 120, 127-138, 2004.
82. Jagetia GC and Rajanikant GK: Effect of curcumin on radiation-impaired healing of excisional wounds in mice. J Wound Care 13, 107-109, 2004.
83. Jagetia GC and Rajanikant GK: Curcumin treatment enhances the repair and regeneration of wounds in mice exposed to hemibody gamma-irradiation. Plast Reconstr Surg 115, 515-528, 2005.
84. Okunieff P, Xu J, Hu D, Liu W, Zhang L, et al.: Curcumin protects against radiation-induced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. Int J Radiat Oncol Biol Phys 65, 890-898, 2006.